Insights
Do child QALYs = adult QALYs? Five reasons why they might not
4 February 2020
Why might differences arise between child and adult QALYs? In the UK, NICE’s science policy and research team is reviewing NICE’s recommendations on child utilities and…
25 Years of the Cost Effectiveness Acceptability Curve
30 December 2019
In 1994 Ben van Hout introduced the concept of the cost effectiveness acceptability curve (CEAC). In the 25 years since, the CEAC has become a standard…
NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study
24 October 2019
As indicated in its recent statement, NICE supports a new valuation study to generate a value set for the EQ-5D-5L. We welcome this announcement. In 2012,…
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
The Trump Administration proposed an International Pricing Index for reimbursing physician-administered Medicare drugs. A conservative thought leader proposed a different basket of ‘market-oriented’ countries. These differ…
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
Market-Driven, Value-Based Advanced Commitment (MVAC) is a new mechanism to help re-direct private-sector R&D investments where they’re needed most. We propose to use MVAC to encourage…
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.